Background: Routine empiric antibiotic therapy is common in patients living with HIV/AIDS.
Such routine antibiotic regimen could lead to selection of multidrug resistance especially ESBLs
in hitherto drug sensitive intestinal colonizing flora. There is paucity of data to describe intestinal
carriage of ESBL-producing enterobacteria in HIV/AIDS patients.
Aim: This study was designed to examine HIV/AIDS patients for faecal carriage with
extendedspectrum beta-lactamase producing enterobacteria at a district care hospital setting in
Methods: A cross-sectional study design was conducted to recruit HIV/AIDS patients at the
Achimota District Hospital in Accra from March through May 2017. Questionnaire-administered
interviews were conducted to determine independent risk factors for ESBL faecal carriage.
Faecal samples were examined for ESBL-producing enterobacteria by serial dilution colony
counts, polymerase chain reaction (PCR) and nucleotide sequencing.
Results: Overall, 43 of 100 patients living with HIV/AIDS had faecal carriage with
ESBLproducing enterobacteria. The predominant ESBL type was CTX-M, mostly blaCTX-M-15.
Among patients colonized with CTX-M-15 positive enterobacteria, these isolates were the
predominant faecal enterobacteria. In such patients, the total faecal ESBL-negative
enterobacteria were the sub-dominant colonies. Two patients were each colonized by isolates that
carried the complex mutant TEM beta-lactamase, blaTEM-121. SHV and OXA type ESBLs were
not identified. In a multivariate logistic regression, the number of persons living with an
HIV/AIDS patient in a household was an independent risk factor for ESBL faecal colonization.
Conclusion. Patients living with HIV/AIDS patients may constitute a significant reservoir of
ESBLs in the hospital and community. The results highlight the need for better surveillance of
ESBLs in the hospital, and Ghana as a whole.
CDR, C (2021). Intestinal Carriage Of Extended-Spectrum Betalactamase Producing Enterobacteria In Hiv/Aids Patient. Afribary.com: Retrieved April 15, 2021, from https://afribary.com/works/intestinal-carriage-of-extended-spectrum-betalactamase-producing-enterobacteria-in-hiv-aids-patient
Coalition, CDR. "Intestinal Carriage Of Extended-Spectrum Betalactamase Producing Enterobacteria In Hiv/Aids Patient" Afribary.com. Afribary.com, 08 Apr. 2021, https://afribary.com/works/intestinal-carriage-of-extended-spectrum-betalactamase-producing-enterobacteria-in-hiv-aids-patient . Accessed 15 Apr. 2021.
Coalition, CDR. "Intestinal Carriage Of Extended-Spectrum Betalactamase Producing Enterobacteria In Hiv/Aids Patient". Afribary.com, Afribary.com, 08 Apr. 2021. Web. 15 Apr. 2021. < https://afribary.com/works/intestinal-carriage-of-extended-spectrum-betalactamase-producing-enterobacteria-in-hiv-aids-patient >.
Coalition, CDR. "Intestinal Carriage Of Extended-Spectrum Betalactamase Producing Enterobacteria In Hiv/Aids Patient" Afribary.com (2021). Accessed April 15, 2021. https://afribary.com/works/intestinal-carriage-of-extended-spectrum-betalactamase-producing-enterobacteria-in-hiv-aids-patient